SG3 Management’s Neurocrine Biosciences NBIX Stock Holding History

SG3 Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-8,500	Closed	-$827K	–	1155
2021 Q2	$827K	Sell	8,500 -16,500	-66%	-$1.58M	0.03%	526
2021 Q1	$2.43M	Buy	+25,000	New	+$2.62M	0.06%	354
2020 Q4	–	Sell	-7,000	Closed	-$676K	–	1154
2020 Q3	$673K	Buy	7,000 +5,000	+250%	+$578K	0.02%	495
2020 Q2	$244K	Buy	+2,000	New	+$221K	0.02%	463

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

EVM

Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

SG3 Management's NBIX Position: Q3 2021 in Review

SG3 Management sold out of Neurocrine Biosciences (NBIX) in Q3 2021, closing a stake of 8,500 shares — an estimated $827K sold.

SG3 Management first reported a position in NBIX in Q2 2020 and held it in 4 quarters. The position peaked at $2.43M in Q1 2021. 395 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

SG3 Management reported no remaining Neurocrine Biosciences position as of Q3 2021 after selling out during the quarter.
SG3 Management sold 8,500 Neurocrine Biosciences shares in Q3 2021, an estimated $827K.
SG3 Management first reported a position in Neurocrine Biosciences in Q2 2020 and held it in 4 quarters.
SG3 Management's Neurocrine Biosciences position peaked at $2.43M in Q1 2021.
395 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on SG3 Management's 13F filing for Q3 2021, filed 15 Nov 2021.